Frankfurt - Delayed Quote EUR

Avricore Health Inc. (8VP1.F)

0.0265
-0.0030
(-10.17%)
As of 8:03:14 AM GMT+2. Market Open.
Loading Chart for 8VP1.F
  • Previous Close 0.0295
  • Open 0.0265
  • Bid 0.0260 x --
  • Ask 0.0415 x --
  • Day's Range 0.0265 - 0.0265
  • 52 Week Range 0.0150 - 0.2020
  • Volume 10,000
  • Avg. Volume 172
  • Market Cap (intraday) 2.934M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date May 28, 2025 - Jun 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a turnkey point-of-care testing platform that turns pharmacies into community point-of-care diagnostic centers. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.

avricore.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 8VP1.F

View More

Performance Overview: 8VP1.F

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

8VP1.F
15.87%
S&P/TSX Composite index (^GSPTSE)
4.05%

1-Year Return

8VP1.F
73.37%
S&P/TSX Composite index (^GSPTSE)
15.17%

3-Year Return

8VP1.F
43.62%
S&P/TSX Composite index (^GSPTSE)
27.45%

5-Year Return

8VP1.F
1.92%
S&P/TSX Composite index (^GSPTSE)
76.55%

Compare To: 8VP1.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 8VP1.F

View More

Valuation Measures

As of 5/13/2025
  • Market Cap

    3.27M

  • Enterprise Value

    3.11M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.00

  • Price/Book (mrq)

    1.86

  • Enterprise Value/Revenue

    1.02

  • Enterprise Value/EBITDA

    8.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -13.98%

  • Return on Assets (ttm)

    4.62%

  • Return on Equity (ttm)

    -33.65%

  • Revenue (ttm)

    4.79M

  • Net Income Avi to Common (ttm)

    -668.98k

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    785.87k

Research Analysis: 8VP1.F

View More